Patient: Page 25

PharmaVoice Team/PharmaVoice

Star Quality

PharmaVOICE is once again honored to pay tribute in the following pages to the Healthcare Businesswomen’s Association (HBA) Rising Stars. The Class of 2006 represents a wide range of disciplines, company types, and levels of accomplishment. These women have one thing in common: they have been ide...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Building on Momentum

Building on Momentum The Forum VIEW on Biotech April 2006 In 2005, biotech companies maintained the momentum that began in 2004, fueled by revenue from marketed biotech drugs ? more than $33 billion in sales. In 2005, Amgen retained its spot as the top bio force with four of the top-...
By PharmaVoice Team • Jan. 2, 2008
Explore the Trendline➔

Stock via Getty Images

Trendline

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff
PharmaVoice Team/PharmaVoice

Drugs in the Real World

By Denise Myshko A greater regulatory focus on safety means companies are under pressure to provide more information about a prescription drug, as well as about the characteristics of patients, once a product becomes available to the larger marketplace. companies are being asked to provide inform...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Medicine Cabinet

Compounds have a one in nine chance of making it through development, according to statistics, but even after reaching the market, each compound faces a whole new set of hurdles: physician adoption, reimbursement, and exposure to supply chain vulnerabilities. December 2005 On the Market Advertisi...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Marketing's New Frontiers

Primed for a Marketing Revolution According to industry experts, there is going to be a shift in marketing that will include: a move away from rational marketing to emotional brand marketing; initiatives that start earlier in the development cycle with end goals identified; marketing programs th...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Change Agents

The Change Agents Identified as vanguards in their respective sectors, these industry leaders are challenging the status quo to make a difference. Dr. Amrit Ray All-Around Global Medical Leadership A passionate leader devoted to bringing new medicines to patients for conditions to which cures hav...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Modern Marketing in the Making

By Elisabeth Pena Modern Marketing in the Making September 2004 VIEW on Marketing Marketing executives from pharmaceutical, biotechnology, device, and diagnostic companies, ranging in size from small specialty to midtier to large and global, share the common challenges of shorter product life ...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The State of Advertising

The State of Advertising The commercialization and promotion of pharmaceutical products depends on relationships for success. The attitudes, personalities, and respect that exist throughout the pharmaceutical advertising landscape play an important role in the evolution of a brand, and are a v...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Talent Pool

executive appointments and promotions in the healthcare industry Pharma POOL Robert Boisclair Dr. Richard Bowles Steve Chellevold Mary-Frances Faraji Brent Saunders Schering-Plough Announces Senior-Level Management Changes Schering-Plough, Kenilworth, N.J., has made senior-level management change...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Value of Phase IV

BY Elisabeth Pena The Value of Phase IV Postmarketing research can be crucial for tracking side effects and exploring new uses for an approved drug. But these trials are heavily scrutinized because some say pharma companies have conducted such studies purely for promotional purposes with little s...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Prioritizing the Pipeline: The Critical Role of Porfolio Management

Prioritizing the Pipeline The critical role of portfolio management Increased pressures on the pharmaceutical industry – shrinking pipelines, rising costs, reimbursement issues, regulatory pressures, and consumer demands – mean companies have to find ways to focus on the projects that will meet c...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Talent Pool

talent pool executive appointments and promotions in the healthcare industry Pharma POOL Robert Bertolini Schering-Plough Appoints Executive VP, Chief Financial Officer Schering-Plough has appointed Robert J. Bertolini as executive VP and chief financial officer. He also serves on the Schering-Pl...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Kareem Saad -- Big Blue's Genomics Ace

By Kim Ribbink Big Blue’s Genomics Ace Young and talented, Kareem Saad, IBM’s worldwide business segment executive for clinical genomics, is overseeing the company’s initiative to take clinical genomics from concept to market. With youthful enthusiasm, innate technical and scientific intelligence...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Talent Pool

Talent Pool Executive Appointments and Promotions in the Healthcare Industry Pharma POOL Joy A. Amundson Bruce McGillivray Jim Utts Baxter Appoints and Promotes Executives Baxter International has named Joy A. Amundson corporate VP and president of its bioscience business. Baxter, Deerfield, Ill....
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

The Secret to Alliance Success

Pharma Forum The Secret to Alliance Success By Denise Myshko Successful partnerships involve more than just signing a contract. Bringing drugs to market and then marketing those products more than ever hinges on how well alliances are managed from a strategic, operational, and organizational stan...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Risky Business

Risky Business By Elisabeth Pena The pharmaceutical industry faces more inherent risks and higher stakes than almost any other industry because its products impact patient safety and well-being. Intensified public and media scrutiny about medication errors and drugs being pulled off the market ha...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Edward J. Ludwig -- A Global Citizen in a Changing World

A Global Citizen in a Changing World By Kim Ribbink BD, a 100-plus-year-old medical-technology company, is blazing a global path with a purpose of helping all people live healthy lives thanks in large part to the progressive and determined efforts of its Chairman, Presid...
By PharmaVoice Team • Jan. 2, 2008
PharmaVoice Team/PharmaVoice

Era of Efficiency -- Provider Selection and the RFP Process

Pharma Forum Era of Efficiency? Provider Selection and the RFP Process By Elisabeth Pena As procurement departments gain a stronger foothold within pharmaceutical companies, service providers are learning how to best work within the RFP process to create meaningful partnerships. Service providers...
By PharmaVoice Team • Jan. 2, 2008